Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

PURPOSE: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ghobrial, Irene M., Gertz, Morie, LaPlant, Betsy, Camoriano, John, Hayman, Suzanne, Lacy, Martha, Chuma, Stacey, Harris, Brianna, Leduc, Renee, Rourke, Meghan, Ansell, Stephen M., DeAngelo, Daniel, Dispenzieri, Angela, Bergsagel, Leif, Reeder, Craig, Anderson, Kenneth C., Richardson, Paul G., Treon, Steven P., Witzig, Thomas E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834498/
https://ncbi.nlm.nih.gov/pubmed/20142598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.0994
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi